<p>The LEAP study was a randomized controlled clinical trial in children at increased risk for peanut allergy, in which intervention using dietary introduction of peanut protein beginning in the first 4 to 11 months of life, continued until age 5 years, significantly decreased the frequency of peanut allergy later in childhood and modulated the immune response to peanuts.</p> <p>All subject phenotype data will be hosted on <a href="https://www.itntrialshare.org/project/Studies/ITN032ADPUBLIC/Study%20Data/begin.view">ITN Trial Share</a> under the LEAP study.</p>

The MALT1 Locus and Peanut Avoidance in the Risk for Peanut Allergy

The MALT1 locus and peanut avoidance in the risk for peanut allergy.